FINNENCE ▪ THE WIRE FILE
THE WIRE · № 90962
Company■ Mixed
New Phase 3 trial: Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders — Azafaros B.V.
KINDCompany
DIRECTION■ Mixed
SOURCES1
ENTITIES0
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.
FULL DISPATCH
Sponsor: Azafaros B.V.; Status: Not Yet Recruiting; Conditions: Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, Gaucher Disease Type 3; Interventions: AZ-3102; Enrollment: 218 (estimated); First posted: 2026-10-21; NCT: NCT07885917
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.